Aflibercept
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Submacular Vascularized Pigment Epithelial Detachments
Conditions
Submacular Vascularized Pigment Epithelial Detachments
Trial Timeline
Nov 1, 2012 → Sep 1, 2015
NCT ID
NCT01722656About Aflibercept
Aflibercept is a approved stage product being developed by Regeneron Pharmaceuticals for Submacular Vascularized Pigment Epithelial Detachments. The current trial status is completed. This product is registered under clinical trial identifier NCT01722656. Target conditions include Submacular Vascularized Pigment Epithelial Detachments.
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01714115 | Pre-clinical | Completed |
| NCT04101721 | Phase 3 | Completed |
| NCT03396861 | Phase 1 | Terminated |
| NCT03085784 | Phase 2 | UNKNOWN |
| NCT02863354 | Phase 2 | Completed |
| NCT02559180 | Approved | Completed |
| NCT02503540 | Approved | Completed |
| NCT02299336 | Approved | Completed |
| NCT02204683 | Phase 1 | Completed |
| NCT01857544 | Approved | UNKNOWN |
| NCT01722656 | Approved | Completed |
| NCT01670162 | Approved | UNKNOWN |
| NCT01617148 | Approved | Completed |
| NCT01495208 | Approved | Withdrawn |